CN115350236A - 用于管理癌症和治疗癌症并存病的方法 - Google Patents

用于管理癌症和治疗癌症并存病的方法 Download PDF

Info

Publication number
CN115350236A
CN115350236A CN202211114854.3A CN202211114854A CN115350236A CN 115350236 A CN115350236 A CN 115350236A CN 202211114854 A CN202211114854 A CN 202211114854A CN 115350236 A CN115350236 A CN 115350236A
Authority
CN
China
Prior art keywords
extract
species
cancer
weight
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202211114854.3A
Other languages
English (en)
Chinese (zh)
Inventor
S·哈尔蒂
J·刘
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Suisse Switzerland Co ltd
Original Assignee
Suisse Switzerland Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Suisse Switzerland Co ltd filed Critical Suisse Switzerland Co ltd
Publication of CN115350236A publication Critical patent/CN115350236A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/577—Malvaceae (Mallow family)
    • A61K36/5777—Theobroma, e.g. cocao or cocoa
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/75—Rutaceae (Rue family)
    • A61K36/752—Citrus, e.g. lime, orange or lemon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/77—Sapindaceae (Soapberry family), e.g. lychee or soapberry
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
    • A61K36/8962—Allium, e.g. garden onion, leek, garlic or chives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Nutrition Science (AREA)
  • Dermatology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN202211114854.3A 2013-11-08 2014-11-07 用于管理癌症和治疗癌症并存病的方法 Pending CN115350236A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361901631P 2013-11-08 2013-11-08
US61/901,631 2013-11-08
PCT/EP2014/074048 WO2015067759A1 (en) 2013-11-08 2014-11-07 Method for the management of cancer and treatment of cancer comorbidities
CN201480060350.5A CN105682671A (zh) 2013-11-08 2014-11-07 用于管理癌症和治疗癌症并存病的方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201480060350.5A Division CN105682671A (zh) 2013-11-08 2014-11-07 用于管理癌症和治疗癌症并存病的方法

Publications (1)

Publication Number Publication Date
CN115350236A true CN115350236A (zh) 2022-11-18

Family

ID=51868963

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202211114854.3A Pending CN115350236A (zh) 2013-11-08 2014-11-07 用于管理癌症和治疗癌症并存病的方法
CN201480060350.5A Pending CN105682671A (zh) 2013-11-08 2014-11-07 用于管理癌症和治疗癌症并存病的方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201480060350.5A Pending CN105682671A (zh) 2013-11-08 2014-11-07 用于管理癌症和治疗癌症并存病的方法

Country Status (16)

Country Link
US (2) US10357531B2 (enExample)
EP (1) EP3065751B1 (enExample)
JP (1) JP6742904B2 (enExample)
KR (1) KR102344748B1 (enExample)
CN (2) CN115350236A (enExample)
AU (1) AU2014345539B2 (enExample)
BR (1) BR112016009931B1 (enExample)
CA (1) CA2928675C (enExample)
DK (1) DK3065751T3 (enExample)
ES (1) ES2777250T3 (enExample)
HK (1) HK1223844A1 (enExample)
MX (1) MX2016006006A (enExample)
PL (1) PL3065751T3 (enExample)
PT (1) PT3065751T (enExample)
RU (1) RU2016117205A (enExample)
WO (1) WO2015067759A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2862598A1 (en) 2013-10-16 2015-04-22 Legacy Healthcare Holding Ltd. Use of a composition for the pigmentation of hair and hairs
WO2017186954A1 (en) * 2016-04-28 2017-11-02 Legacy Healthcare Ltd Method for the improvement of speed and endurance capacity
EP3886838A4 (en) * 2018-11-30 2022-08-10 Beth Israel Deaconess Medical Center, Inc. COMPOSITIONS AND METHODS FOR REDUCING MAJOR THROMBOTIC EVENTS IN CANCER PATIENTS
FR3109881B1 (fr) * 2020-05-07 2022-10-21 Legacy Healthcare Switzerland Sa Procede pour ameliorer le systeme immun pour acquerir la pan-immunite
US11819530B1 (en) 2023-05-17 2023-11-21 Legacy Healthcare (Switzerland) Sa Long term treatment of hair loss

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101631529A (zh) * 2007-02-13 2010-01-20 传世健康护理控股有限公司 新型化妆品和/或药物组合物及它们的应用
WO2011005310A1 (en) * 2009-07-07 2011-01-13 Robert Shorr Pharmaceutical composition
WO2012113820A1 (en) * 2011-02-23 2012-08-30 Legacy Healthcare Holding Ltd New use of compositions for preventing chemotherapy and radiotherapy induced alopecia (cria), reducing cria impact and improving the appearance of hair re-growth after cria

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2844614A1 (de) 1978-10-13 1980-05-08 Alfred Czypull Bio-aktiv-haartinktur
JPH04342517A (ja) 1990-07-20 1992-11-30 Yutaka Miyauchi ５α−リダクターゼ阻害剤
CH682217A5 (en) 1991-05-23 1993-08-13 Linda Singer Dolla Hair lotion comprising aq. alcoholic extract of natural plant material - and aromatic plant substances and prepn., for treating or preventing baldness
FR2706771A1 (en) 1993-06-21 1994-12-30 Pelletier Jacques Formula for the treatment of certain cancers.
JP3233813B2 (ja) 1995-03-31 2001-12-04 株式会社マンダム チロシナーゼ生合成促進剤及び白髪改善用又は白髪防止用頭髪用化粧料並びに日焼け用化粧料
DE19533777A1 (de) 1995-09-12 1997-03-13 Walther Aria Ellen Haarwuchsmittel
JP3527584B2 (ja) 1996-01-23 2004-05-17 株式会社ナリス化粧品 養毛・育毛剤
US5773241A (en) 1996-09-05 1998-06-30 Ericsson; Arthur Dale Preparation of bioactive extracts
JP2000044439A (ja) 1998-07-31 2000-02-15 Shiseido Co Ltd 頭皮頭髪用組成物
JP2000247830A (ja) 1999-02-26 2000-09-12 Nagase & Co Ltd エラスターゼ阻害剤
EP1228769A1 (de) 2001-02-02 2002-08-07 Jörg-Peter Prof. Schür Symbiontisches Regenerativum
US6582702B2 (en) * 2001-07-10 2003-06-24 Alvin Foster Rigby Herbal tonic composition that improves respiration, aids in the elimination of toxins and improves overall vitality
US20030077336A1 (en) 2001-10-10 2003-04-24 Maf Group, Llc Anti-inflammatory complex containing flaxseed oil
JP2003201229A (ja) 2001-10-23 2003-07-18 Shiseido Co Ltd マトリックスメタロプロテアーゼ活性阻害剤および抗老化用化粧料
US20030105104A1 (en) * 2001-11-27 2003-06-05 Burzynski Stanislaw R. Formulation of amino acids and riboflavin useful to reduce toxic effects of cytotoxic chemotherapy
BR0203591A (pt) * 2002-09-05 2004-05-25 Marc Kipfer Bebida reidratante e energética natural a base de água-de-coco, sucos de frutas e componentes nutritivos incorporados
DE102004011968A1 (de) 2004-03-10 2005-09-29 Henkel Kgaa Präbiotisch wirksame Pflanzenextrakte
MY142017A (en) * 2004-03-19 2010-08-16 Nestec Sa Composition comprising all essential nutrients of a fruit or a plant material with increased stability and bioavailability and process of forming the same
KR20070022018A (ko) 2004-03-19 2007-02-23 네스텍소시에테아노님 기능성 재료의 전달
US20060018867A1 (en) 2004-05-12 2006-01-26 Ichimaru Pharcos Co., Ltd Cosmetic composition and production thereof
WO2005120452A1 (en) 2004-06-07 2005-12-22 Katica Pavlovic A procedure in production of a curative creams for regeneration of skin tissue, easer breathing, psoriasis, pains and tiredness in legs
FR2865132A1 (fr) 2004-07-06 2005-07-22 Oreal Utilisation de la diosmetine, d'un de ses derives ou d'un extrait de plante contenant l'un d'eux pour favoriser la pigmentation de la peau et/ou des cheveux
DE202004012348U1 (de) 2004-08-03 2004-10-07 Jabal Amman, Suhbi Hasan Mohammes Zubereitung zur Pflege der Haut bei Psoriasis oder Ekzem
US7462595B2 (en) * 2004-09-17 2008-12-09 Prange Jr Arthur Jergen Methods for treating cancer-related fatigue
JP2006104098A (ja) 2004-10-04 2006-04-20 Ichimaru Pharcos Co Ltd ヒアルロニダーゼ活性阻害剤
FR2877219B1 (fr) 2004-10-28 2007-03-09 Fatima Basri Composition utilisee en cosmetique ou en pharmacologie pour stimuler la synthese du collagene
FR2877576B1 (fr) 2004-11-08 2007-03-09 Ahmed Kadri Composition pharmaceutique utilisee pour stimuler la proliferation et l'activation des mastocytes
DE102005010142A1 (de) 2005-03-02 2005-11-03 Dr. Kurt Wolff Gmbh & Co. Kg Mittel zur Aktivierung der Haarwurzeln und Verwendung des Mittels
JP4804805B2 (ja) 2005-06-10 2011-11-02 横関油脂工業株式会社 細胞賦活剤、紫外線障害緩和剤及びメラニン産生抑制剤
WO2008015341A2 (fr) 2006-08-03 2008-02-07 Societe D'extraction Des Principes Actifs Sa (Vincience) Utilisation d'un extrait vegetal en tant qu'agent actif pour augmenter la synthese de melanine dans les melanocytes
US8088431B2 (en) * 2007-03-14 2012-01-03 The Hershey Company Health bars and compositions for improving mental and physical energy
US20080305096A1 (en) 2007-06-07 2008-12-11 Unicity International, Inc. Method and composition for providing controlled delivery of biologically active substances
FR2939646B1 (fr) 2008-12-12 2017-04-14 Oreal Procede de coloration capillaire a partir d'une composition comprenant au moins un orthodiphenol, un sel metallique, du peroxyde d'hydrogene, du (bi)carbonate et un agent alcalinisant
RU2567801C2 (ru) * 2009-06-22 2015-11-10 Ск Биофармасъютиклс Ко., Лтд. Способы лечения и профилактики усталости
WO2012017361A2 (en) 2010-08-05 2012-02-09 Legacy Healthcare Holding Ltd Method for stimulating hair growth
WO2012140013A2 (en) 2011-04-11 2012-10-18 Legacy Healthcare Holding Ltd New use of compositions for the treatment of inflammatory skin conditions, scaly scalp conditions and collagen remodeling.
WO2013020719A2 (en) * 2011-08-09 2013-02-14 Legacy Healthcare Holding Ltd New use of compositions to delay the onset of the catagen phase of the hair
EP2862598A1 (en) 2013-10-16 2015-04-22 Legacy Healthcare Holding Ltd. Use of a composition for the pigmentation of hair and hairs

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101631529A (zh) * 2007-02-13 2010-01-20 传世健康护理控股有限公司 新型化妆品和/或药物组合物及它们的应用
WO2011005310A1 (en) * 2009-07-07 2011-01-13 Robert Shorr Pharmaceutical composition
WO2012113820A1 (en) * 2011-02-23 2012-08-30 Legacy Healthcare Holding Ltd New use of compositions for preventing chemotherapy and radiotherapy induced alopecia (cria), reducing cria impact and improving the appearance of hair re-growth after cria

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
刘宏森: "酒店餐饮金牌服务员培训手册 最新版", 天津科技翻译出版公司 *

Also Published As

Publication number Publication date
CA2928675A1 (en) 2015-05-14
CA2928675C (en) 2023-09-05
PL3065751T3 (pl) 2020-07-13
KR102344748B1 (ko) 2021-12-30
EP3065751A1 (en) 2016-09-14
AU2014345539A8 (en) 2016-05-26
EP3065751B1 (en) 2019-12-18
US20190314441A1 (en) 2019-10-17
PT3065751T (pt) 2020-03-06
ES2777250T3 (es) 2020-08-04
MX2016006006A (es) 2016-07-18
US10357531B2 (en) 2019-07-23
HK1223844A1 (zh) 2017-08-11
BR112016009931B1 (pt) 2021-02-02
WO2015067759A1 (en) 2015-05-14
AU2014345539B2 (en) 2020-04-23
CN105682671A (zh) 2016-06-15
JP6742904B2 (ja) 2020-08-19
US20160256512A1 (en) 2016-09-08
AU2014345539A1 (en) 2016-05-19
DK3065751T3 (da) 2020-03-09
JP2016535753A (ja) 2016-11-17
KR20160074006A (ko) 2016-06-27
RU2016117205A (ru) 2017-12-11
RU2016117205A3 (enExample) 2018-08-09

Similar Documents

Publication Publication Date Title
US20190314441A1 (en) Method For The Management Of Cancer And Cancer Treatment-Related Comorbidities
JP2007518805A5 (enExample)
JP2012522762A5 (enExample)
JP6209579B2 (ja) 補助化療薬品とされる医薬組成物その用途
Ariel Therapeutic effects of hydroxyurea. Experience with 118 patients with inoperable solid tumors
WO2017148129A1 (zh) 一种用于治疗恶病质的药物组合物及其应用
PT1549329E (pt) Extracto que apresenta uma actividade anticancerosa e uma actividade antitóxica
TW200538466A (en) Methods for controlling angiogenesis and cell proliferation
HK40077741A (en) Method for the management of cancer and treatment of cancer comorbidities
WO2022068918A1 (zh) 包含酸碱中和组合的药物组合物及其应用
EP1877043B1 (en) Use of paeonol for inhibiting angiogenesis or for enhancing radiosensitization
IL316641A (en) Methods for treating Cushing's syndrome and liver disorders, and reducing liver toxicity from medications administered to the patient
JP2024522163A5 (enExample)
CN106421796B (zh) 索拉菲尼联合ccr4拮抗剂在抑制癌生长及转移中的应用
CN118141867B (zh) 一种以鹿角人参为君药治疗乳腺癌的药物及制备方法和应用
JP2021533107A (ja) 癌を治療するための併用療法
CN117224514B (zh) 一种化合物、组合物及其在制备治疗心律失常的药物中的应用
CN105769884B (zh) 一种治疗肺癌的药物组合物
CN112533605A (zh) 用于治疗癌症的组合疗法
CN105193810B (zh) 5‑氟尿嘧啶组合物及其在制备抗肿瘤注射剂中的应用
CN102091062A (zh) 一种采取吸入给药紫杉醇治疗肺癌的方法
JP2024017060A (ja) Ｔｉｅ２活性化剤
EP1203585A1 (en) Anti-ischemic agent
US9872882B2 (en) Aurantiamide dipeptide derivatives for treatment or prevention of angiogenesis-related diseases
WO2022122040A1 (zh) 白果内酯或银杏内酯组合物在制备镇静药物中的应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40077741

Country of ref document: HK

RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20221118